In this report we describe the contribution of prostaglandin E 2 (PGE 2 ) derived from the inducible microsomal PGE-synthase type-1 (mPGES-1) to the epidermal growth factor receptor (EGFR) oncogenic drive in tumor epithelial cells and in tumor-bearing mice. EGFR stimulation upregulated expression of mPGES-1 in HT-29, A431 and A549 cancer cells. Egr-1, a transcription factor induced by EGF, mediated this response. The Egr-1 rise provoked the overexpression of mPGES-1 messenger and protein, and enhanced PGE 2 formation. These changes were suppressed either by silencing Egr-1, or by upstream blockade of EGFR or ERK1/2 signals. Further, in a clonogenic assay on tumor cells, EGF induced a florid tumorigenic phenotype, which regressed when mPGES-1 was silenced or knocked down. EGF-induced mPGES-1 overexpression in epithelial cell reduced E-cadherin expression, whereas enhancing that of vimentin, suggesting an incipient mesenchymal phenotype. Additionally, inhibiting the EGFR in mice bearing the A431 tumor, the mPGES-1 expression and the tumor growth, exhibited a parallel decline. In conclusion, these findings provide novel evidence that a tight cooperation between the EGF/EGFR and mPGES-1 leads to a significant tumorigenic gain in epithelial cells, and provide clues for controlling the vicious association.
Introduction
Prostaglandins, mainly prostaglandin E 2 (PGE 2 ) , have assumed to have an important role in cancer biology because evidence demonstrates their involvement in cancer development as they exert a tumorigenic action. The clearest evidence has been the observation that overexpression of the inducible cyclooxygenase-2 (COX-2), and as a consequence, increased PGE 2 synthesis, was causally associated with the growth and aggressiveness of human colon cancer (Eberhart et al., 1994; Wiesner et al., 2001 ). These observations were later extended to many other solid tumors (Menter et al., 2010) .
PGE 2 is a well-known mediator of inflammation, and it is evident that PGE 2 exerts pleiotropic effects in tumors, promoting proliferation, survival, angiogenesis, migration and invasion. This multitude of PGE 2 effects has been attributed to pro-survival and proliferative signals including: PI3K/Akt (Tessner et al., 2004) , MAPK-ERK1/2 (Pozzi et al., 2004) , cyclic adenosine monophosphate/protein kinase A (Leone et al., 2007) , epidermal growth factor receptor (EGFR) (Pai et al., 2002; Buchanan et al., 2003; Donnini et al., 2007) and activation of b-catenin/ T cell factor (TCF) in colorectal cancer cells (Castellone et al., 2005) and in hepatocarcinogenesis (Lu et al., 2012) .
Recent investigations have focused on PGE 2 synthases (microsomal PGE-synthase type-1 (mPGES-1), mPGES-2 and cPGES), specifically on mPGES-1. Although cPGES and mPGES-2 are constitutively expressed at relatively low levels, mPGES-1 is highly inducible (Samuelsson et al., 2007) . All enzymes, being downstream of COX-2, act selectively on PGE 2 synthesis, and inhibition of PGE 2 synthases would circumvent the issue of blocking the formation of protective prostaglandins associated with COX-2 inhibitors.
mPGES-1 upregulation has been detected in many epithelial tumors (Yoshimatsu et al., 2001a, b; Golijanin et al., 2004; Choe et al., 2005) , and its silencing has been reported to reduce pre-neoplastic lesions (Nakanishi et al., 2008) . mPGES-1 tumorigenic potential has also been demonstrated in cell cultures, exemplified by HEK293 cells, in which co-transfection of COX-2 and mPGES-1 induced an increase in proliferation in vitro. Also when these engineered cells were inoculated in nude mice in vivo, large and vascularized tumors were formed (Kamei et al., 2003 (Kamei et al., , 2009 . Despite the evidence linking mPGES-1 and tumorigenesis, most studies investigating the inducible nature of the enzyme in cultured cells have been performed using a variety of inflammatory stimuli (LPS, IL-b, TNFa and others) (Naraba et al., 2002; Cheng et al., 2004; Subbaramaiah et al., 2004) , whereas little is known about the behavior of the enzyme in tumor cells challenged with oncogenic stimuli.
Here, we show that mPGES-1 is upregulated in cultured epithelial tumor cells exposed to EGF, an oncoprotein, which, through its receptor EGFR, is responsible for tumorigenesis in a wide array of solid tumors (Ciardiello and Tortora, 2008) . We used three cell lines, representative of colon (HT-29), epidermoid (A431), and lung (A549) tumors, examining the mPGES-1 expression following EGFR activation by EGF. We also studied the contributions of transcription factors (for example, Egr-1, NFkB) relevant to mPGES-1 expression, as well as the signaling pathway downstream of EGFR activation (ERK1/2). The tumorigenic profile of epithelial cells was analyzed by the clonogenic assay, and by evaluating the potential development of a mesenchymal transition phenotype through the assessment of E-cadherin and vimentin expression in wild-type (WT) and mPGES-1 knockdown (Kd) tumor cells. We also investigated the effect of inhibiting the EGFR in tumor-bearing mice on mPGES-1 expression and tumor growth, finding a parallel decline of both. The results of this study provide further evidences for the pro-tumorigenic role of PGE 2 in epithelial cells of diverse lineage as we demonstrate the existence of a tight link between the EGF/EGFR, Egr-1, and mPGES-1 molecular pathway and tumor progression.
Results

EGFR activation upregulates mPGES-1 expression
The EGFR ligand, EGF (25 ng/ml), upregulated mPGES-1 expression in colon HT-29, epidermoid A431 and lung A549 carcinoma cells, both at protein (18 h, Figures 1a and b) and messenger level (6 h, Figure 1c ). The enzyme upregulation was accompanied by increased PGE 2 secretion, ranging from 2.3-to 2.7-fold over control, depending on the cell line (Figure 1d ). On the contrary, neither mPGES-2 nor cPGES expression were significantly modified by EGF treatment (Figure 1a) . EGF also induced COX-2 expression, although the time and extent of upregulation was different for the three cell lines (Figure 1a, see legend) .
To further explore the EGFR-mediated upregulation of mPGES-1, we studied mPGES-1 promoter-driven transcription in the cell lines, after transfection with report gene plasmids bearing fragments of the mPGES-1 gene promoter differing in nucleotide length (from-1100 to þ 30). EGF consistently augmented mPGES-1 transcription, expressed either as fold induction relative to the empty plasmid, or absolute values of relative luciferase units ( Figure 2a and Table 1 , respectively). The variable extent of mPGES-1 induction observed in the cell lines used was dependent on cell phenotype and on the length of the mPGES-1 promoter (Table 1) . The shorter plasmid (from À154 to þ 30), containing GCrich elements, was sufficient to drive the mPGES-1 transcription (Figure 2a ). This suggests that Egr-1, an
Figure 1 EGF promotes mPGES-1 expression and activity. (a) Analysis of mPGES-1, mPGES-2, cPGES and COX-2 in three cancer cell lines (HT-29, A431 and A549) in response to EGF (25 ng/ml, 18 h for mPGES-1, mPGES-2 and cPGES, and 4 h for COX-2 in HT-29 and A431, and 8 h in A549). (b) Quantification of mPGES-1 expression in HT-29, A431 and A549. Data are reported as arbitrary density unit (ADU) and represents the ratio between mPGES-1/Actin expression of three independent blots (***Po0.01). (c) Quantitative PCR for mPGES-1 mRNA expression in cells exposed to EGF (25 ng/ml) or fresh medium (Control, 6 h). mPGES-1 mRNA expression reported as fold increase compared with basal levels (n ¼ 3). (***Po0.001; **Po0.05). (d) EIA immunoassay for PGE 2 production, expressed as pg/ml (n ¼ 3), in cells treated with EGF (black bar, 25 ng/ml) or fresh medium (white bar, Control) in presence of arachidonic acid (10 mM, 24 h) (***Po0.001).
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mPGES-1 upregulation requires ERK1/2 and Egr-1 activation downstream to EGFR We studied the expression of Egr-1 in tumor cells exposed to EGF. Because EGF/EGFR signaling is known to promote solid tumor growth through activation of the MAPK/ERK1/2 pathway (Dasari and Messersmith, 2010) , we evaluated ERK1/2 involvement in the expression of mPGES-1. Indeed, EGF (25 ng/ml) induced Egr-1 expression and ERK1/2 phosphorylation in the three cell lines analyzed in a time-dependent manner, both events peaking between 15 and 45 min ( Figure 2b) .
Next, we studied the EGF-induced activation of Egr-1 analyzing both its translocation from the cytosol to the nucleus (western blot and immunocytochemistry), and the induction of its transcriptional activity. Egr-1 translocation was evidenced by the time-related enrichment of protein in HT-29 cell nuclear fractions, and by immunofluorescence in the nucleus (Figures 2c and d) . Similarly, we observed an increase, in all cell lines, of luciferase activity of Egr-1-Pro36LUC, a reporter gene plasmid containing two Egr-1 binding sites inserted upstream of a prolactin minimal promoter (Figure 2e ), demonstrating that EGF induces both Egr-1 expression and activity.
A number of experiments firmly established the involvement of EGFR-MAPK pathway in Egr-1 and mPGES-1 expression. Thus, blockers of either EGFR or ERK1/2 (AG1478, and U0126, respectively) suppressed the EGF-induced upregulation of both Egr-1 and mPGES-1 in all cell lines examined ( Figure 2f ).
The involvement of Egr-1 in inducing mPGES-1 in tumor cells was further documented by Egr-1 knocked down. In fact, silencing Egr-1 in epithelial tumor cells, abolished the increased expression provoked by EGF (Figure 3a) , concomitantly reducing the mPGES-1 induction ( Figure 3a) . Conversely, in experiments in which tumor cells were transfected with the Egr-1 expression plasmid pLNCX-NGFI-A (Clone Egr-1 þ / þ ), we found that higher levels of Egr-1 expression (clone Egr-1 þ / þ ) corresponded to higher mPGES-1 protein levels (Figure 3b , Po0.001). Further, in tumor cells silenced for Egr-1, EGF failed to induce transcription of mPGES-1 (Figure 3c ). Additional evidence for the role of Egr-1 was obtained by performing the chromatin immunoprecipitation assay (ChIP) assay in HT-29 cells treated with EGF for 45 min. In these conditions, Egr-1 was found to be specifically bound to the mPGES-1 promoter only in cells stimulated by the growth factor, whereas binding in control cells was negligible ( Figure 3d ). Thus, EGF promotes the recruitment of Egr-1 toward the mPGES-1 gene promoter.
All together, these data demonstrate the requirement for ERK1/2/Egr-1 pathways downstream of EGFR for induction of mPGES-1 expression.
Silencing mPGES-1 expression reduces epithelial cell tumorigenicity The role of mPGES-1 expression on the cell tumorigenic potential following EGFR activation was assessed by the clonogenic assay. Although EGF induced colony formation in both HT-29 and in A549 cells, mPGES-1 gene Kd in either cell types reduced by 3-to 5-fold the EGFR response ( Figure 4a ).
This suggests that mPGES-1/PGE 2 signaling is involved in the malignancy induced by EGF. E-cadherin and vimentin are well-established biomarkers of enhanced malignancy, signaling the initiation of epithelialmesenchymal transition process (Thiery et al., 2009) . Indeed, in A549 cells WT, or cells transfected with non target shRNA, EGF decreased E-cadherin, whereas vimentin expression was increased (Figure 4b ). Conversely, in A549 Kd for mPGES-1, EGF failed to regulate both proteins-mediated adhesion/movement. Thus, mPGES-1 appears to control the EGF/EGFR oncogenic drive by governing the development of the epithelial-mesenchymal transition program (Figure 4b ).
Tumor growth decline, caused by EGFR blockade, is associated with downregulation of mPGES-1 expression The functional association between EGFR and mPGES-1 signaling was further investigated in mice bearing human A431 xenograft, which expresses high EGFR levels (Johns et al., 2002) . A431 cells (10 7 cells) were inoculated in nude mice. Treatment with vehicle control (0.5% methylcellulose) or the EGFR inhibitor AG1478, (400 mg/mice, 10 days) started 4 days after cells implantation, a time at which tumors were measurable mPGES-1 modulates EGFR-mediated malignancy S Donnini et al (3 mm diameter). Tumor size in controls increased steadily, reaching an average volume of 400 mm 3 , 7-fold higher at day 10, relative to day 4. AG1478 administration reduced tumor growth by 50% or more, starting from day 8 (Po0.01), relative to the vehicle-group (Figure 5a ). During the course of treatment, neither body-weight loss nor signs of toxicity were observed. In AG1478-treated tumors, mPGES-1 expression, analyzed by western blot and immunohistochemistry, was significantly reduced relative to control specimens (Figures 5b and c, Po0.05) . Consistently, mPGES-1 expression in tumor samples correlated with tumor volume (Figure 5b ).
Discussion
The keen interest in prostaglandin biosynthesis stems from the recognition that PGE 2 exerts an important role in the initiation and progression of several epithelial tumors (Menter et al., 2010) . In this study, we focused on mPGES-1 examining its induction in cultured epithelial tumor cells (HT-29, colon, A431, squamous cell, and A549, lung adenocarcinoma) following stimulation by EGF. Although a number of reports have described the relationship between mPGES-1 overexpression and tumor growth, the evidence that the enhanced malignancy is linked to a transduction loop between the prostanoid and the EGF system is fragmentary (Hanaka et al., 2009; Nah et al., 2010; Wang and Dubois, 2010; Lu et al., 2012) . Our aim was to demonstrate that the mPGES-1/PGE2 and the EGF axis provide a cohesive program for malignancy in epithelium. Here, we demonstrated that EGFR stimulation induces mPGES-1 upregulation and increases PGE 2 production, through the specific activation of gene transcription pathway, that is, Egr-1, in epithelial tumor cells of diverse lineage (see below). In addition, we show that epithelial cells expressing mPGES-1 evolve toward a distinct tumor phenotype, and produce a fast-growing tumor mass when inoculated in nude mice.
The EGF-induced mPGES-1 expression, preceded by the rise of its encoding mRNA, was similar in the three cell lines examined. In the promoter region of the mPGES-1 gene, several binding sites for transcription factors have been identified, including GC boxes for Egr-1 transcription factor was immunoprecipitated from cells stimulated with EGF (25 ng/ml) for 45 min. Immunoprecipitated DNA was amplified with specific primers for the mPGES-1 proximal promoter region. As a positive control, PCR was performed on chromatin fragments isolated before immunoprecipitation ( þ ). Immunoprecipitation with a normal rabbit serum was carried out in parallel as negative control (À). Shown is a representative experiment of the three experiment performed.
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Egr-1, NFkB, AP-1 and c/EBP response elements (Dı´az-Mun˜oz et al., 2010) . The detailed analysis of the mPGES-1 promoter (from-1100 to þ 30), performed by transfecting tumor cells with mPGES-1 promoter constructs of different length, revealed a consistent enhancement of the EGF-driven mPGES-1 transcription, enabling also to identify the minimal sequence, containing solely the Egr-1 binding sequence, capable of eliciting a response. The ChIP assay corroborated these observations by showing the Egr-1-specific binding within the mPGES-1 promoter. Thus, these findings delineate the role of Egr-1 in the EGFR-induced expression of the mPGES-1 gene in epithelial tumor cells. The interplay between mPGES-1 and Egr-1 expression was clearly demonstrated by experiments involving either Egr-1 silencing through siRNA, or forcing its expression through transfection with the pLNCX-NGFI-A Egr-1 plasmid, resulting in abrogation of mPGES-1 promoter activity and expression or mPGES-1 overexpression, respectively. Although these data clearly point to Egr-1 as an important transcription factor of mPGES-1 gene expression following EGF/ EGFR stimulation, one ought to consider the vast redundancy of signals present in neoplastic epithelial cells. Among the wide repertoire of pro-inflammatory stimuli known to induce mPGES-1 gene (phorbol 12-myristate 13-acetate (PMA), IL-1b, TNFa or lipopolysaccharide (LPS)), recently some of us described the involvement of NFkB in both Egr-1 and mPGES-1 expression in macrophages exposed to LPS (Dı´az-Mun˜oz et al., 2010) . Indeed, in HT-29 tumor cells, inhibition of NF-kB activity by an IKK inhibitor prevented the EGF-induced mPGES-1 overexpression (data not shown), suggesting that also in tumor cells the mPGES-1 transcription could be controlled by several transcription factors, whose action might be exerted in cell and context-dependent manner (Naraba et al., 2002; Cheng et al., 2004; Lin and Karin, 2007; Deckmann et al., 2010; Dı´az-Mun˜oz et al., 2010) . Inhibition of NF-kB activity precludes from distinguishing from its transcriptional effect on mPGES-1 by direct binding of mPGES-1 promoter or indirectly, by altering Egr-1 expression (Dı´az-Mun˜oz et al., 2010) .
The connection between EGF/EGFR and mPGES-1 in promotion of tumorigenicty in epithelial cells, so far largely surmised from work on non-tumor cells (that is, synoviocytes) (Nah et al., 2010) , is clearly demonstrated here by two lines of evidence. First, the clonogenic assay showed that abrogation of the mPGES-1 gene in tumor epithelial cells (HT-29) markedly reduced the EGF tumorigenic potential. Second, blockade of EGFR by AG1478 (a TK receptor inhibitor) in vivo in an A431 epithelial tumor xenograft model gave reduced mPGES-1 expression and decreased tumor growth. To be noted that this tumor line features the highest inducible mPGES-1 and PGE 2 levels among the cells examined (see Figure 1 ) and a very robust EGF/EGFR system (Johns et al., 2002) .
The PGE 2 leveraging effect on EGF tumorigenic action has been explained according to various mechanisms, among which, the transactivation of EGFR has been the most studied (Pai et al., 2002; Buchanan et al., 2003; Donnini et al., 2007) . However, also reported mechanisms involving the regulation of E-cadherin expression by PGE 2 might contribute to enhance tumorigenesis in solid cancer (Dohadwala et al., 2006; Mann et al., 2006) . Thus, PGE 2 has been shown to suppress E-cadherin expression, through the transcriptional repression of Snail and ZEB genes (Dohadwala et al., 2006) . Furthermore, the EGF-induced Snail expression leads to PGE 2 increase in colon tumor cells by inhibiting PGDH, the main degrading enzyme for prostanoids in tumors (Mann et al., 2006) . It is of interest that Egr-1 has been reported to induce Snail by binding to its promoter, thus acting as a trigger for the epithelial mesenchymal transition (Grotegut et al., 2006) . Indeed, the marked changes of E-cadherin and vimentin expression, noted here in A549 WT but not in mPGES-1 Kd, provide evidence for the relevance of mPGES-1 in the incipient epithelial to mesenchymal transition, a process which confers enhanced tumorigenic properties to epithelial cells, in terms of invasion and ability to form metastasis. Additionally, the mPGES-1/PGE 2 biosynthetic pathway might contribute to cancer progression through other cytokine/growth factors, as exemplified by the reported synergism between PGE 2 and FGF-2/FGFR1 system in sustaining tumor vascularity (Finetti et al., 2009 ). 
The number of mechanisms in which PGE 2 and consequently mPGES-1, is involved in boosting the EGF-driven tumorigenicity in epithelial cells, signal its key role in rewiring cells toward a tumor phenotype. Conceivably, strategies aimed to interfere with mPGES-1 signaling might be a valuable addition to the armamentarium for controlling epithelial tumor progression.
Materials and methods
Reagents
Reagents were as follows: AG1478, IKK inhibitor VII and U0126 (Calbiochem, Darmstadt, Germany); anti-b-actin, antivimentin (Sigma, Milan, Italy); anti-mPGES-1, anti-mPGES-2, anti-cPGES and anti-COX-2 antibodies (Cayman Chemical, Vincibiochem, Florence, Italy); EGF (RELIAtech, Wolfenbuttel, Germany), anti phospho-p44/42 MAPK, anti-EGFR (Cell Signalling, Pero, Italy); anti Egr-1 (Santa Cruz, Heidelberg, Germany); anti-E Cadherin antibodies (DAKO, Milan, Italy). Where not indicated, reagents were from Sigma.
Cell lines
HT-29, human colorectal adenocarcinoma cells, A431 human epidermoid carcinoma and A549 human lung carcinoma cells were obtained from ATCC (Milan, Ital) and cultured as recommended. A549 WT, mPGES-1 Kd and non-target shRNA cells were obtained and cultured as described (Hanaka et al., 2009) .
Western blotting 4 Â 10 5 cells were plated in 60 mm dishes, serum deprived (0.1%. fetal calf serum, 24 h), then exposed to EGF in the presence or absence of MAPK, EGFR or NFkB inhibitors. To assess the translocation of Egr-1 from cytosol to nucleus, after treatment with EGF for the indicated times, cells were scraped/ trypsinized, and homogenized on ice in a lysis buffer, containing 0.1 mM ethylene glycol tetraacetic acid (EGTA), 0.1 mM EDTA, 10 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), 10 mM KCl, protease and phosphatase inhibitors. After incubation on ice for 15 min, Nonidet-P-40 was added to cell lysates, which were centrifuged (10 000 r.p.m., 30 s). The supernatant contains the cytosolic fraction, whereas the pellet was solubilized in lysis buffer containing 1 mM EGTA, 1 mM EDTA, 20 mM HEPES, 10 mM NaCl, 1%protease and phosphatase inhibitors, followed by incubation on ice for 10 min and centrifugation (14 000 r.p.m., 5 min). The supernatant contains the nuclear fraction. An equal amount of proteins were loaded on SDS-polyacrylamide gel and then transferred to a nitrocellulose membrane. Western blotting was performed as described (Donnini et al., 2007) . Images were digitalized with CHEMI DOC Quantity One program, blots were analyzed in triplicate by densitometry using NIH Image 1.60B5 software, and the arbitrary densitometric units were normalized to arbitrary densitometric units for b-actin.
PGE 2 immuno-assays PGE 2 was measured by an enzyme immunoassay (EIA) kit (Prostaglandin E 2 EIA kit-Monoclonal, Cayman Chemical). Cells were exposed to EGF (25 ng/ml, 24 h) and treated with 10 mM arachidonic acid. Cell culture supernatants were assayed directly at a final dilution of 1:10 to 1:500. PGE 2 concentration was expressed as pg/ml, normalized to total protein concentration.
Real-time PCR
Total RNA was obtained using RNA mini kit (Qiagen, Inc., Milan, Italy). RNA (0.5 mg) was reverse transcribed using an RT-PCR kit (Applied Biosystems, Foster City, CA, USA). mPGES-1 modulates EGFR-mediated malignancy S Donnini et al mPGES-1 mRNA detection was measured using the optimized TaqMan assay-on-demand (Applied Biosystems) and the expression of the mRNAs in each sample was calculated by referring to an external reference curve generated with universal human reference RNA (Stratagene, La Jolla, CA, USA). The results were expressed as fold increase.
Luciferase activity Cells were transiently transfected with luciferase constructs containing different deletions of the murine promoter of mPGES-1 cloned in the pxP2-LUC plasmid: mPGES-1-1100 (À1100 to þ 30) mPGES-1-895 (À895 to þ 30), mPGES-1-483 (À483 to þ 30) and mPGES-1-154 (À154 to þ 30), or with a construct containing two Egr-1 consensus binding sites insert upstream of a prolactin minimal promoter (Egr-1-Pro36LUC) (Dı´az-Mun˜oz et al., 2010; Crosby et al., 1991) .
Transfections were performed using Effectene Transfection Reagents (Qiagen) according to manufacturer's instructions. Transfection efficiency was assessed by co-transfection with a plasmid harboring the Renilla luciferase gene under control of a constitutive promoter (Promega, Madison, WI, USA). 24 h following transfection, cells were starved for 24 h and stimulated for 18 h (mPGES-1 LUC) or 45 min (Egr-1-Pro36LUC) with EGF (25 ng/ml) and then lysed. Luciferase reporter assays were performed using Steady Glo and dual luciferase reporter assay reagents (Promega), and activity was measured using a Tecan Infinite 200Pro. Luciferase activity was normalized according to the protein expression for each condition.
Transfection
For siRNA transfection: the siRNAs sequences (human mPGES-1: 5 0 -CGGGCTAAGAATGCAGACTTT-3 0 , Egr-1: 5 0 -CCCGTCGGTGGCCACCACGTA-3 0 ) were from Qiagen. The day before transfection, cells were trypsinized and 3 Â 105 cells were seeded in six-well plates. Transient transfection of siRNA was carried out using HT-29 transfection reagent (Altogen, Las Vegas, NV, USA) according to the manufacturer instructions. Cells were assayed 48 h after transfection.
For DNA transfection: transient transfection of Egr-1 expression plasmid pLNCX-NGFI-A (Clone Egr-1 þ / þ ) generously provided by Dr AM Pe´rez-Castillo (Instituto de Investigaciones Biome´dicas, Madrid, Spain) (Pignatelli et al., 1999) , was carried out using Effectene transfection reagent (Qiagen) according to the manufactures instructions. Cells were assayed 48 h after transfection.
Chromatin immunoprecipitation assay
ChIP assays were performed as described (Dı´az-Mun˜oz et al., 2010) . HT-29 cells (6 Â 10 6 ) were maintained in RPMI with 0.5% fetal calf serum for 24 h before stimulation with EGF for 45 min. Cells were then fixed with 1% formaldehyde for 5 min at 37 1C and lysed in ice-cold lysis buffer (10 mM HEPES, 1.5 mM MgCl 2 , 10 mM KCl, 0.5 mM dithiothreitol (DTT), 0.1% NP-40 and protease inhibitors) for 10 min at 4 1C. Nuclei pellet was suspended in nuclear lysis buffer (50 mM Tris-HCl pH 8, 10 mM EDTA, 1% SDS and protease inhibitors) and incubated on ice for 10 min. DNA was shared by sonication and lysates were cleared by centrifugation and diluted in ChIP dilution buffer (50 mM Tris-HCl pH 8, EDTA 5 mM, NaCl 200 mM, and 0.5% NonidetP-40). Lysates were precleared with salmon sperm/protein A-agarose. A sample of 'input DNA' (positive control ( þ )) was collected at this point. Protein-DNA complexes were immunoprecipitated overnight at 4 1C with 2 mg of the anti-Egr-1 or non-immune rabbit serum as a control (negative control (À)). Antibody-protein-DNA complexes were then captured using salmon sperm DNA/protein A agarose for 30 min followed by washes with wash buffer (20 mM Tris-HCl pH 8, 2 mM EDTA, 0.1% SDS, 1% NP-40, and 500 mM NaCl) and TE buffer (20 mM Tris-HCl, and 2 mM EDTA). The protein/DNA complexes were eluted using extraction buffer (20 mM Tris-HCl, 2 mM EDTA, and 2% SDS) and disrupted by heating at 65 1C overnight followed by proteinase K treatment for 2 h at 45 1C. DNA was extracted with a DNA Purification system (Promega). PCR was conducted using promoter-specific primers (Applied Biosystem,): mPGES-1, sense 5 0 -TCCGGCAACTGCTTGTCTTT CTCT-3 0 and antisense 5 0 -TGTGATCAGCTCGACAGAG GAGCA-3 0 . PCR products obtained after 35 cycles were separated on 2% agarose gels.
Immunofluorescence analysis HT-29 cells (3 Â 10 4 cells/well on glass cover-slips placed into 24-multiwell plates) were serum starved and treated with EGF for 45 min. Cells were fixed in paraformaldehyde for 5 min and then washed in phosphate buffer saline with Ca 2 þ and Mg 2 þ . Cells were then permeabilized in 0.25% Tween-20 in phosphate buffer saline for 10 min. After the blocking of unspecific bindings in 3% bovine serum albumin for 30 min the cells were incubated overnight at 4 1C with a polyclonal antibody against Egr-1 (Santa Cruz) diluted 1:40 in phosphate buffer saline/0.5% bovine serum albumin. Samples were then incubated with secondary antibody TRITC conjugated (Sigma) and assessed by fluorescence microscope (Eclipse TE300, Nikon, Florence, Italy) at 40 Â magnification and images taken by a digital camera.
Clonogenic assay
For clonogenic assay, HT-29 cells, after silencing for mPGES-1, and A549 cells, WT, non-target shRNA, or Kd were incubated with EGF (25 ng/ml) for 18 h. Following EGF treatment, cells were plated in 60 mm culture dishes (HT-29 at a density of 2000 cells/dish, A549, 150 cells per dish) in medium containing 10% fetal calf serum, and then kept in a humidified incubator at 37 1C and 5% CO 2 for 3 or 2 weeks, respectively. Colonies (475 cells) with 50% plate efficiency were fixed and stained with 0.05% crystal violet (Sigma) in 10% ethanol and counted.
In vivo tumor xenograft Experiments have been performed in accordance with the EC guidelines and National Ethical Committee. Immunodeficient mice (5-week-old female athymic nude mice, Harlan, Milan, Italy) were subcutaneously inoculated in the right flank with 10 7 A431 cells in 50 ml/phosphate buffer saline. After 4 days, when tumors reached a 70-100 mm 3 volume, animals were randomly assigned to two different experimental protocols. At this time, intraperitonealy AG1478 treatment (400 mg/mouse, daily, eight mice), or vehicle (0.05% methylcellulose, eight mice) started. Mice were treated with 200 ml volume intraperitonealy, for 10 consecutive days. Data are reported as tumor volume (mm 3 ). Animals were observed daily for signs of cytotoxicity, and at day 10 they were killed by CO 2 asphyxiation, and tumors were collected and split in two parts. One part was immediately frozen in liquid nitrogen for western blotting as described (1), the other part was embedded in Tissue-Tek O.C.T. (Sakura, San Marcos, CA, USA), for histology. Seven thick cryostat sections from tissue samples were stained with hematoxylin and eosin, and adjacent sections were used for immunohistochemical staining with the anti-mPGES-1 (Cayman). Cryostat sections were first fixed in acetone at 20 1C and incubated for mPGES-1 modulates EGFR-mediated malignancy S Donnini et al 10 min in 3% H 2 O 2 , washed in TBS, then incubated in a blocking reagent (KIT Immunoperoxidase Secondary Detection System, Chemicon, Milan, Italy). Anti-m-PGES-1 diluted 1:100 (5 mg/ml) in TBS and 0.05% bovine serum albumin was applied for 1 h at room temperature. Sections were then washed (TBS) and incubated for 10 min in the appropriate speciesspecific biotinylated secondary antibodies (goat anti-rabbit IgG, KIT Immunoperoxidase Secondary Detection System, Chemicon). After washing, the sections were incubated for 10 min in streptavidin-conjugated HRP and exposed to 3,3-diaminobenzidine tetrahydrocloride for 8 min to produce a brown reaction product. Sections were then counterstained in hematoxylin and mounted in Aquatex (Merck, Rahway, NJ, USA). Western blotting analysis for mPGES-1 was performed as reported above (see Western blotting analysis).
Statistical analysis
Results are expressed as means ± s.e.m. Statistical analysis was performed using the Student's t test, analysis of variance or
